Foley Hoag has a long history of extensive involvement with the development of legislation and regulations affecting the biotechnology, pharmaceutical, medical device and healthcare provider industries. Our clients include a number of leading pharmaceutical, biotechnology and medical device companies regarding government strategies for legislative, regulatory and administrative matters.
learn more
-
On the Agenda: Law and the Environment, Financing Growth, and Non-Competes—Foley Hoag Launches Three New Blogs
[Read More]
-
Foley Hoag Launches New Microsite for Law Students as 2009 On-campus Interviews Commence
[Read More]
-
Working Mother and Flex-Time Lawyers Recognize Foley Hoag
[Read More]
-
Foley Hoag Joins American Lawyer's Select Group of Top 50 A-List Firms
[Read More]
-
Live @ BIO 2008: Innovation, Commercialization, and Protecting Assets
[Read More]
Publications more
- Coverage and Reimbursement for Molecular Diagnostics: Current Issues and Options [Read More]
- Hatch-Waxman Safe Harbor Inapplicable to Research Tools [Read More]
- Massachusetts House and Senate Pass Compromise Restrictions on Pharmaceutical & Medical Device Marketing [Read More]
- Medicare Datasheet [Read More]
- Food and Drug Datasheet [Read More]
Client Successes more
-
Orphan Drug Act
Our lawyers represented clients under the Orphan Drug Act, which is credited with giving rise to the biotechnology industry, through its provision of seven years of marketing exclusivity to companies that develop drugs or biologics for patients with rare diseases. [Read More]
-
Reimbursement Strategies in the Fight Against Cancer
We represented a leading biotechnology company in increasing hospital outpatient reimbursement for supportive anti-cancer therapy. [Read More]
Attorney advertising. Prior results do not guarantee a similar outcome. Copyright © 2008 Foley Hoag LLP. All rights reserved.